covid
Buscar en
Infectio
Toda la web
Inicio Infectio Comparación de métodos de microdilución CLSI M27-A2 y EUCAST en aislamientos ...
Journal Information
Vol. 14. Issue S2.
Pages 107-115 (December 2010)
Share
Share
Download PDF
More article options
Vol. 14. Issue S2.
Pages 107-115 (December 2010)
Open Access
Comparación de métodos de microdilución CLSI M27-A2 y EUCAST en aislamientos de Candida spp. en pacientes con cáncer
CLSI microdilution M27-A2 and EUCAST method comparison for Candida spp. in patients with cancer
Visits
3714
Carolina Duarte1, Ninna Pulido1, Pilar Rivas2,3, Ricardo Sánchez3,4, Jorge A. Cortés3,
Corresponding author
jorgecortes@yahoo.com

Correspondencia Dirección: Facultad de Medicina, Of. 510, Universidad Nacional de Colombia, Calle 45, carrera 30, Ciudad Universitaria, Bogotá, D.C., Colombia. Teléfono: (57) 1 3165000 Ext. 15011.
, Sonia Cuervo3,5, Claudia Parra1
1 Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
2 Grupo de Micología Médica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
3 Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia
4 Grupo Investigación-clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
5 Grupo de Infectología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
This item has received

Under a Creative Commons license
Article information
Resumen
Objetivo

comparar los métodos de referencia de microdilución en caldo de la CLSI M27-A2 y EUCAST, identificando la utilidad y las principales diferencias de cada uno de ellos para los agentes antifúngicos anfotericina B(1), fluconazol (FCZ) e itraconazol (ITZ), contra aislamientos clínicos de Candida spp. de pacientes con cáncer.

Materiales y métodos

se estudiaron 136 aislamientos de C. albicans, 36 de C. tropicalis y 17 de Candida spp. Se utilizó el índice Kappa ponderado para medir el grado de acuerdo entre los dos métodos.

Resultados

se estableció que el grado de concordancia entre los dos métodos para el total de los aislamientos fue alto con AB (κ: 1) y FCZ (κ: 0.74) y bajo al utilizar ITZ (κ: 0.49). La concordancia fue variable y especie-específica: para ITZ y FCZ en C. albicans fue de 0,45 y 0,64; en C. tropicalis, de 0,48 y 0,91; y en Candida spp. de 0,73 y 0,87, respectivamente.

Discusión

este estudio sugiere que las pruebas de sensibilidad antifúngica para los dos métodos son equivalentes en lo esencial. Deben considerarse las diferencias y discrepancias asociadas a la especie implicada, el tipo de antifúngico utilizado y los tiempos de incubación, que puede producir variaciones al interpretar los resultados obtenidos de acuerdo con la metodología empleada.

Palabras claves:
agentes antifúngicos/*farmacología
Candida/*efectos de drogas/aislamiento y purificación
candidiasis/microbiología
humanos
pruebas de sensibilidad microbiana/métodos
fluconazol
anfotericina B
itraconazol
Abstract
Objective

compare the broth microdilution testing reference standards CLSI M27-A2 and EUCAST, identifying the usefulness of each one of them and their main differences, against the antifungal agents amphotericin B(1), fluconazole (FCZ), and itraconazole (ITZ) using clinical isolates of Candida spp. in cancer patients.

Methods

isolates of C. albicans (n=136), C. tropicalis (n=36), and Candida spp. (n=17) were tested by the two methods. The Kappa index was used to establish the degree of agreement between the methods.

Results

the degree of agreement between the two methods was high for AB (κ:1) and FCZ (κ: 0.74) and was low for ITZ (κ: 0.49). Agreement was variable and specific for the various species: for ITZ and FCZ in C. albicans, it was 0.45 and 0.64, respectively. In C. tropicalis, it was of 0.48 and 0.91, and in Candida spp., it was 0.73 and 0.87 respectively.

Discussion

this study suggests that antifungal susceptibility testing using both methods is equivalent. Attention should be focused on differences and discrepancies associated with the species tested, the type of antifungal agent, and the incubation times, which can cause variations at the moment of interpreting the results obtained.

Key words:
Antifungal Agents/*pharmacology
Candida/*drug effects/isolation & purification
Candidiasis/microbiology
Humans
Microbial Sensitivity Tests/methods
Fluconazole
Amphotericin B
Itraconazole
Full text is only aviable in PDF
Referencias
[1.]
C. De Bedout, J. Ayabaca, R. Vega, M. Méndez, A.R. Santiago, M.L. Pabon, et al.
Evaluación de susceptibilidad de especies de Candida al fluconazol usando el métodos de difusión en disco.
Biomédica., 23 (2003), pp. 31-37
[2.]
J.H. Rex, M.A. Pfaller, T.J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M.A. Ghannoum, et al.
Antifungal susceptibility testing: practical aspects and current challenges.
Clin Microbiol Rev., 14 (2001), pp. 643-658
[3.]
J.L. Finquelievich.
Candidiasis.
Enfermedades infecciosas, sexta ed., pp. 268-274
[4.]
Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standards M27-A2. Wayne, Pa.:National Committe for Clinical Laboratory Standards: 2002.
[5.]
M. Cuenca-Estrella, C.B. Moore, F. Barchiesi, J. Bille, E. Chryssanthou, D.W. Denning, et al.
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).
Clin Microbiol Infect., 9 (2003), pp. 467-474
[6.]
M. Cuenca-Estrella, T.M. Diaz-Guerra, E. Mellado, J.L. Rodriguez-Tudela.
Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.
J Clin Microbiol., 39 (2001), pp. 525-532
[7.]
M. Cuenca-Estrella, W. Lee-Yang, M.A. Ciblak, B.A. Arthington-Skaggs, E. Mellado, D.W. Warnock, et al.
Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.
Antimicrob Agents Chemother., 46 (2002), pp. 3644-3647
[8.]
M. Cuenca-Estrella, L. Rodero, G. Garcia-Effron, J.L. Rodriguez-Tudela.
Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999.
J Antimicrob Chemother., 49 (2002), pp. 981-987
[9.]
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MIC of antifungal agents for fermentative yeasts.
Clin Microbiol Infect., 14 (2008), pp. 398-405
[10.]
M.A. Pfaller, M. Bale, B. Buschelman, M. Lancaster, A. Espinel-Ingroff, J.H. Rex, et al.
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods.
J Clin Microbiol., 32 (1994), pp. 1650-1653
[11.]
M.A. Pfaller, W.L. Yu.
Antifungal susceptibility testing.
New technology and clinical applications. Infect Dis Clin North Am., 15 (2001), pp. 1227-1261
[12.]
P. Rivas.
Antifungal susceptibility testing in clinical isolates of Candida spp from patients with cancer.
Rev Colomb Cancerol., 8 (2004), pp. 22-28
[13.]
J.H. Rex, M.A. Pfaller, J.N. Galgiani, M.S. Bartlett, A. Espinel-Ingroff, M.A. Ghannoum, et al.
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections.
Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis., 24 (1997), pp. 235-247
[14.]
J.R. Landis, G.G. Koch.
The measurement of observer agreement for categorical data.
Biometrics, 33 (1977), pp. 159-174
[15.]
J. Cohen.
Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit.
Psychol Bull., 70 (1968), pp. 213-220
[16.]
S. Takakura, N. Fujihara, T. Saito, T. Kudo, Y. Iinuma, S. Ichiyama.
Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection.
Eur J Clin Microbiol Infect Dis., 23 (2004), pp. 380-388
[17.]
M.A. Slavin, T.C. Sorrell, D. Marriott, K.A. Thursky, Q. Nguyen, D.H. Ellis, et al.
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
J Antimicrob Chemother., 65 (2010), pp. 1042-1051
[18.]
A. Espinel-Ingroff, F. Barchiesi, M. Cuenca-Estrella, M.A. Pfaller, M. Rinaldi, J.L. Rodriguez-Tudela, et al.
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
J Clin Microbiol., 43 (2005), pp. 3884-3889
[19.]
F.C. Odds, L. Vranckx, F. Woestenborghs.
Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation.
Antimicrob Agents Chemother., 39 (1995), pp. 2051-2060
[20.]
A. Gomez-Lopez, M.C. Arendrup, C. Lass-Floerl, J.L. Rodriguez-Tudela, M. Cuenca-Estrella.
Multicenter comparison of the ISO standard 20776-1 and the serial 2-fold dilution procedures to dilute hydrophilic and hydrophobic antifungal agents for susceptibility testing.
J Clin Microbiol., 48 (2010), pp. 1918-1920
[21.]
J.L. Rodriguez-Tudela, J. Berenguer, J.V. Martinez-Suarez, R. Sanchez.
Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans.
Antimicrob Agents Chemother., 40 (1996), pp. 1998-2003
[22.]
S.C. Lee, C.P. Fung, J.S. Huang, C.J. Tsai, K.S. Chen, H.Y. Chen, et al.
Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.
Antimicrob Agents Chemother., 44 (2000), pp. 2715-2718
Copyright © 2010. Asociación Colombiana de Infectología (ACIN)
Download PDF
Article options